<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01823406</url>
  </required_header>
  <id_info>
    <org_study_id>HUM00060967</org_study_id>
    <secondary_id>1DP3DK094292-01</secondary_id>
    <nct_id>NCT01823406</nct_id>
  </id_info>
  <brief_title>Tissue-Specific Metabolic Reprogramming in Diabetic Complications</brief_title>
  <acronym>DP3</acronym>
  <official_title>Tissue-Specific Metabolic Reprogramming in Diabetic Complications. Glycemic Clamp Studies to Determine the Real Time Synthesis Rates of Glucose Derived Metabolites in Individuals With Type 1 Diabetes and Healthy Controls.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We will perform blood sugar studies to assess changes in metabolic (biochemical processes&#xD;
      that occur within us) profiles associated with high blood sugar and diabetes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective: To assess steady state and dynamic metabolite changes in subjects with type 1&#xD;
      diabetes with and without microvascular complications and to understand intrinsic differences&#xD;
      from non-diabetics in metabolite levels and flux.&#xD;
&#xD;
      The hypothesis is that diabetic complications arise from tissue-specific metabolic&#xD;
      reprogramming resulting in alterations in fuel utilization which lead to dysfunction of the&#xD;
      tissue. To test this hypothesis, we will use sensitive and specific mass spectrometer based&#xD;
      metabolomic analysis to measure steady state metabolite levels in plasma and urine from&#xD;
      controls subjects and subjects with T1DM, without and with diabetic complications during&#xD;
      euglycemic and hyperglycemic clamp studies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">August 2017</completion_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in the levels of TCA cycle metabolites between groups during euglycemia and hyperglycemia</measure>
    <time_frame>One time study visit /subject for an average of up to 24 h.</time_frame>
    <description>Investigators will perform 4 hour Euglycemic and 4 hr hyperglycemic glucose clamps on each subject once. The Investigators will have 4 different groups of subjects. At specific time points during the clamps, the investigators will draw blood samples for measurement of metabolic assays and flux . The investigators will also collect spot urine samples for metabolic assay and flux.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Type 1 Diabetes no complications.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each cohort group will be admitted to the Michigan Clinical Research Unit for Blood glucose Clamp studies. Each subject will have a Euglycemic clamp (normal blood sugar clamp) for 4 hours and a hyperglycemic clamp (elevated blood sugar to 300) for 4 hours. Once the subject is clamped, bloods and urine will be collected to assay for specific metabolomics and proteomic biomarkers. We will perform the same clamps for each cohort.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Type 1 Diabetes with microalbuminuria</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each cohort group will be admitted to the Michigan Clinical Research Unit for Blood glucose Clamp studies. Each subject will have a Euglycemic clamp (normal blood sugar clamp) for 4 hours and a hyperglycemic clamp (elevated blood sugar to 300) for 4 hours. Once the subject is clamped, bloods and urine will be collected to assay for specific metabolomics and proteomic biomarkers. We will perform the same clamps for each cohort.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Type 1 Diabetes with advanced complications.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each cohort group will be admitted to the Michigan Clinical Research Unit for Blood glucose Clamp studies. Each subject will have a Euglycemic clamp (normal blood sugar clamp) for 4 hours and a hyperglycemic clamp (elevated blood sugar to 300) for 4 hours. Once the subject is clamped, bloods and urine will be collected to assay for specific metabolomics and proteomic biomarkers. We will perform the same clamps for each cohort.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aged and sex matched healthy control volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each cohort group will be admitted to the Michigan Clinical Research Unit for Blood glucose Clamp studies. Each subject will have a Euglycemic clamp (normal blood sugar clamp) for 4 hours and a hyperglycemic clamp (elevated blood sugar to 300) for 4 hours. Once the subject is clamped, bloods and urine will be collected to assay for specific metabolomics and proteomic biomarkers. We will perform the same clamps for each cohort.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Euglycemic clamp (normal blood sugar clamp) for 4 hours</intervention_name>
    <arm_group_label>Aged and sex matched healthy control volunteers</arm_group_label>
    <arm_group_label>Type 1 Diabetes no complications.</arm_group_label>
    <arm_group_label>Type 1 Diabetes with advanced complications.</arm_group_label>
    <arm_group_label>Type 1 Diabetes with microalbuminuria</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>hyperglycemic clamp (elevated blood sugar to 300) for 4 hours</intervention_name>
    <arm_group_label>Aged and sex matched healthy control volunteers</arm_group_label>
    <arm_group_label>Type 1 Diabetes no complications.</arm_group_label>
    <arm_group_label>Type 1 Diabetes with advanced complications.</arm_group_label>
    <arm_group_label>Type 1 Diabetes with microalbuminuria</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Group 1: T1DM subjects without complications:&#xD;
&#xD;
        Group 2: T1DM subjects with microalbuminuria . Group 3: T1DM subjects with advanced&#xD;
        diabetes complications Group 4: Age-and-sex-matched healthy control subjects .&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
        General entry criteria:&#xD;
&#xD;
        Must have type 1 diabetes &gt; 5 years duration. 18 years of age or older&#xD;
&#xD;
        Subjects in the microalbuminuria group will have a history of urinary microalbumin to&#xD;
        creatinine ration between 30-300 m/g confirmed on repeat testing while the non-albuminuric&#xD;
        group will have a value of less than 30 mg/g.&#xD;
&#xD;
        Subjects in advanced complications group will have confirmed Retinopathy, Peripheral and/or&#xD;
        Autonomic Neuropathy and nephropathy.&#xD;
&#xD;
        Non diabetic individuals will be matched for age and gender and will have normal glucose&#xD;
        tolerance, normal lipid metabolism, and normal blood pressure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Age less than 18 . Women of child-bearing potential who may be pregnant or lactating&#xD;
        History of pancreas, kidney or liver transplant History of drug or alcohol use. History of&#xD;
        cancer other than basal cell carcinoma or squamous cell skin cancer. Presence of a&#xD;
        condition that in the opinion of the investigator would make it unlikely for the subject to&#xD;
        complete the study.&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rodica Pop-Busui, MD,PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>March 19, 2013</study_first_submitted>
  <study_first_submitted_qc>March 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2013</study_first_posted>
  <last_update_submitted>June 26, 2018</last_update_submitted>
  <last_update_submitted_qc>June 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Rodica Pop-Busui</investigator_full_name>
    <investigator_title>Associate Professor Internal Medicine, MEND Division</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Diabetes Complications</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

